Health News Releases

  • Today March 26
The past 12 months have marked one of the most prolific periods of product innovation in Hyperice‘s
March 25, 15:50
Hyperice Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
Hyperice (https://hyperice.com/), a high-performance wellness brand, has been named to Fast Company’s (https://www.fastcompany.com/) prestigious list of the World’s Most Innovative Companies of 2026.
March 24, 16:39
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs
Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual
Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Libr
March 24, 15:20
Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova
March 23, 15:50
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.
March 20, 15:52
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting
Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22,
Samsung Bioepis office in Songdo, Incheon, Republic of Korea
March 18, 16:38
Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates
Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under d
March 18, 15:55
DNA Script Expands Global Access to On-demand DNA Synthesis With Distributor Agreements in Latin America and East Asia
DNA Script, a pioneer in DNA synthesis providing scientists with rapid, on-demand access to high-quality DNA, today announced it has signed distribution agreements with Gencell (https://cts.businesswi
March 17, 16:20
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse
March 17, 16:00
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies
Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics por
SBC Medical Announces Opening of Brand Flagship “NEO Skin Clinic Ginza.”
March 17, 11:30
SBC Medical Announces Opening of Brand Flagship “NEO Skin Clinic Ginza.”
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields,
March 16, 09:23
Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide
Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research collaboration and license agreement with
WHOOP and Samuel Ross MBE Announce First Limited-Edition Collection Drop for PROJECT TERRAIN
March 15, 13:30
WHOOP and Samuel Ross MBE Announce First Limited-Edition Collection Drop for PROJECT TERRAIN
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%3Futm_source%3DPR%26utm_medium%3DPR%26utm_campaign%3DSR_A&esheet=54443959&newsitemid=20260312513358&lan=en-US&anc
March 13, 15:55
C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests to Help Doctors Diagnose Alzheimer’s Disease
C2N Diagnostics, LLC (https://c2n.com/) (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, has reached an agreement with BeauBrain Healthcare (https://beaubra
March 13, 11:40
Andersen Consulting Strengthens Platform with Collaborating Firm Ambit Iberia
Andersen Consulting expands its technology and business transformation capabilities through a Collaboration Agreement with Ambit Iberia, a consulting firm specializing in digital and regulatory soluti
March 12, 16:10
Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets
Veristat (https://www.veristat.com/), a global clinical research organization (CRO) and consultancy specializing in complex studies, announced expanded regulatory and clinical trial services to intern
March 12, 15:55
InterSystems Appoints Former NHS and Mass General Leader Dr. Tim Ferris as Vice President, Healthcare Practice
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced the appointment of Tim Ferris, M.D., as Vice President, Healthcare Practice. T
The Hypervolt 3 line enables users to massage away stress and tension, loosen muscle knots, maintain
March 12, 15:10
Hyperice Introduces Hypervolt 3 Line: More Powerful, Quieter, and Longer-Lasting Percussion Massage Devices
Hyperice (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhyperice.com%2F&esheet=54442271&newsitemid=20260310934508&lan=en-US&anchor=Hyperice&index=1&md5=9dae1327c39b94f4b0ce095f7d63
March 12, 08:36
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site
Chiesi Group (“Chiesi”), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, t
March 11, 15:53
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF
March 11, 15:52
Galderma Completes Successful Placement of EUR 500 Million Eurobond
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Grou
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker
March 11, 15:45
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2Fus%2Fen%2F&esheet=54439889&newsitemid=20260310966566&lan=en-US&anchor=WHOOP&index=1&md5=45c5be6cf83ed6f2f43c9ea
March 11, 08:44
For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025
Ferring today published its 2025 Annual Report (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ferring.com%2Fwp-content%2Fuploads%2Fsites%2F16%2F2026%2F03%2FFerring-Pharmaceutic
March 10, 09:43
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin
Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily
Medical Korea 2026 will take place at Coex, Seoul, from March 19 (Thu) to 22 (Sun), themed on ‘AI-Po
March 06, 16:22
Medical Korea 2026 Spotlights AI-Powered Global Healthcare Transformation and Cross-Border Medical Services
Medical Korea 2026 (https://www.mkconf.org/fairDash.do?hl=ENG), the 16th Global Healthcare & Medical Tourism Conference, will take place March 19-22, 2026, at COEX in Seoul. Hosted by the Ministry
March 05, 16:04
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency, and Core EBITDA of 1.211 billion USD, Growing 18.9% at Constant Currency
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. · Record net sales of 5,207 million USD, surpassing 5 billion
WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform
March 05, 15:40
WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform Globally
WHOOP (https://www.whoop.com/kr/en/), the human performance company, today announced plans to add more than 600 new roles across Software, Research & Design, Hardware, Product, and Marketing as the co
March 05, 09:20
Linnea Achieves CEP Certification for Cannabidiol Isolate
Linnea is proud to announce that its Cannabidiol (CBD) Isolate has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP). The CEP serves to attest that the quality of an act
Swiss Advanced Vision premium IOL lenses for cataract surgery
March 04, 15:50
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance
Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cata
March 04, 11:11
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54436160&newsitemid=20260301580219&lan=en-US&anchor=TSE%3A4502%2FNYSE%
Controller and processor, Filter-less culture bag and reservoir/waste bags *Controller and other acc
March 03, 15:45
PHCbi Launches LiCellGrow™ Cell Expansion System to Support High-Quality and Efficient Production of Cell and Gene Therapies
PHC Corporation’s Biomedical Division (Head Office: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereinafter “PHCbi”), a global provider of laboratory sample storage and cell cultivation solutions
March 03, 14:20
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova
Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data
March 02, 13:30
Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data
Cowellnex Co., Ltd. (Cowellnex)—jointly established by Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and Kyowa Kirin Co., Ltd. (Kyowa Kirin)—and Metagen, Inc. (Metagen), which promotes
March 02, 11:55
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54433496&newsitemid=20260226660598&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md
February 27, 15:39
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results
February 27, 14:30
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acqui
February 25, 15:58
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane prod
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies
February 24, 16:26
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies
Angelini Pharma (https://www.angelinipharma.com/), part of the privately owned Angelini Industries, and Quiver Bioscience (https://www.quiverbioscience.com/) (“Quiver”), a discovery technology and the
February 24, 16:10
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusi
Rare Diseases: Collaboration is key. image: AdobeStock_1308212316
February 24, 10:15
AOP Health on Rare Diseases: Information. Collaboration. Innovation.
Between 27 and 36 million[1] people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment[2]. Progress in diagnosis and treatment is ofte
February 22, 09:40
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency
YolTech Therapeutics (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.yoltx.com%2F&esheet=54428688&newsitemid=20260219197004&lan=en-US&anchor=YolTech+Therapeutics&index=1&md5=5e9
February 20, 09:57
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54427813&newsitemid=20260218745615&lan=en-US&anchor=TSE%3A4
Michael Clay, Caidya's Chief Operating Officer
February 18, 13:05
Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development
Caidya (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.caidya.com%2F&esheet=54426559&newsitemid=20260217431202&lan=en-US&anchor=Caidya&index=1&md5=7b2712d1d79f058b73bc0260a86357
February 18, 09:09
Galderma Announces Appointment of New Chief Financial Officer
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte wi
February 13, 16:00
Angelalign Technology Inc. (6699.HK) Says a Preliminary European Court Ruling on Certain Software Features Will Have Minimal Impact on Users
Angelalign Technology Inc. (6699.HK) (“Angel”) said a ruling by the Unified Patent Court of Düsseldorf, Germany that it preliminarily cease its use of certain software functions that automatically upd
February 12, 15:22
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties
Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients
February 11, 15:30
Kirin and Immunosens Launch Joint Development of a Self-Testing Service That Uses Urinary IgA to Visualize a Person’s Immune Status
Kirin Holdings Company, Limited (Kirin Holdings) and Immunosens Co., Ltd. (Immunosens) have begun the joint development of a unique “Self-Testing Service[1]” designed to visualize a person’s immune st
February 11, 15:13
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™
Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT based hyaluronic acid injectables ever authorized in J
February 10, 17:30
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54421686&newsitemid=20260210380286&lan=en-US&ancho
February 06, 15:50
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Grou
February 06, 11:40
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading oncol
25 per page50 per page75 per page100 per page